HRT 916K
Latest Information Update: 29 Oct 2018
At a glance
- Originator sanofi-aventis
- Developer Toyama Chemical
- Class Antibacterials
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 09 Sep 2002 Discontinued - Phase-I for Bacterial infections in Japan (PO)
- 22 Dec 1999 Hoechst has merged with Rhône-Poulenc to form Aventis